Cartesian Therapeutics (RNAC) Enterprise Value (2016 - 2026)

Cartesian Therapeutics (RNAC) has reported Enterprise Value for 12 consecutive years, with -$1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 99.06% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at -$1.7 million (up 99.06% YoY), while the FY2025 annual figure was -$125.1 million, up 41.14% from the prior year.
• Enterprise Value improved to -$1.7 million in Q1 2026 per RNAC's latest filing, from -$125.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$1.7 million in Q2 2025 and bottomed at -$219.2 million in Q3 2024.
• Historically, Enterprise Value has averaged -$109.9 million across 5 years, with a median of -$117.4 million in 2022.
• Annual changes were most pronounced in 2024 — Enterprise Value plunged 176.44% — and 2025, when it jumped 99.22%.
• Cartesian Therapeutics' Enterprise Value stood at -$134.6 million in 2022, then jumped by 42.86% to -$76.9 million in 2023, then plunged by 176.44% to -$212.6 million in 2024, then soared by 41.14% to -$125.1 million in 2025, then surged by 98.64% to -$1.7 million in 2026.
• Business Quant data shows RNAC's Enterprise Value at -$1.7 million in Q1 2026, -$125.1 million in Q4 2025, and -$1.7 million in Q3 2025.